|
Novartis delivered solid performance in the first quarter
|
24 April 2013 |
|
Supreme Court denial of Glivec patent clarifies limited intellectual property protection and discourages future innovation in India
|
01 April 2013 |
|
Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
|
21 March 2013 |
|
Novartis collaboration aims to eliminate rheumatic heart disease (RHD) in Zambia, Africa
|
28 February 2013 |
|
Novartis delivers strong innovation in 2012, offsetting patent expirations; next growth phase expected to begin in 2013
|
23 January 2013 |
|
Novartis makes progress in the fight to eliminate leprosy worldwide
|
21 January 2013 |
|
Phase III data show significant benefit of Novartis drug Afinitor® in patients with non-cancerous tumors associated with TSC
|
13 January 2013 |
|
Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease
|
16 December 2012 |
|
Novartis highlights key data in patients with hematologic diseases and breast cancer
|
28 November 2012 |
|
Novartis receives FDA approval for Flucelvax®
|
21 November 2012 |